Baird maintains Inspire Medical Systems at Neutral, raises price target to $77 from $73
Baird kept its Neutral rating on Inspire Medical Systems but increased its price target to $77 from $73, suggesting a 14.6% upside from the Nov 2 close of $67.21, according to the firm.
How this was made

The 30-second read
Why it matters
The price target increase signals a modest upside potential, but limited catalyst depth keeps impact modest.
Market read
A small-cap medical device stock receives a modest analyst upgrade, offering limited trading opportunity.
What to watch
No mention of new product trials or regulatory milestones.
Background
Analyst rating changes can influence short-term price moves, especially for small-cap stocks.
Ticker impact
Baird raised its price target for Inspire Medical Systems to $77 from $73, indicating a fresh analyst upgrade.
likely upward pressure as investors price in the higher target
Target raise suggests improved outlook; no other catalysts present.
Market effects
None significant beyond the company.
Minimal impact on broader market.
Limited to niche medical device sector.
Counterpoint
The upgrade may be premature if upcoming clinical data disappoints.
Key entities
- Analyst FirmBaird
Provided the rating upgrade and new price target.
- CompanyInspire Medical Systems
Medical device maker receiving the upgraded target.



